PubMed: Cannabidiol: metabolism and clinical efficacy in epileptic patients

PubMed: Cannabidiol: metabolism and clinical efficacy in epileptic patients

Expert Opin Drug Metab Toxicol. 2024 Mar 11. doi: 10.1080/17425255.2024.2329733. Online ahead of print.

ABSTRACT

INTRODUCTION: The landscape of epilepsy treatment has undergone a significant transformation with the emergence of cannabidiol as a potential therapeutic agent. Epidiolex, a pharmaceutical formulation of highly purified CBD, garnered significant attention not just for its therapeutic potential but also for being the first cannabis-derived medication to obtain approval from regulatory bodies.

AREA COVERED: In this narrative review the authors explore the intricate landscape of CBD as an antiseizure medication, deepening into its pharmacological mechanisms and clinical trials involving various epileptic encephalopathies. This exploration serves as a comprehensive guide, shedding light on a compound that holds promise for individuals contending with the significant challenges of drug-resistant epilepsy.

EXPERT OPINION: Rigorous studies highlight cannabidiol’s efficacy, safety profile, and potential cognitive benefits, warranting further exploration for its approval in various drug-resistant epilepsy forms. As a promising therapeutic option, cannabidiol not only demonstrates efficacy in seizure control but also holds the potential for broader enhancements in the quality of life, especially for patients with epileptic encephalopathies.

PMID:38465404 | DOI:10.1080/17425255.2024.2329733

https://pubmed.ncbi.nlm.nih.gov/38465404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Ds1JEbG0OWaBdqM3tTUGjkFhFGaOtMecPdpuvzbuubWi6d9Fn&fc=20231022105433&ff=20240311072239&v=2.18.0.post9+e462414 March 11, 2024 10:00 am